BCHE and neurodegenerative disease: Organoruthenium complexes are very promising not only as anticancer agents but also as agents for symptomatic therapy of neurodegenerative diseases due to their inhibitory properties against both acetycholinesterase (AChE) and butyrylcholinesterase (BChE), as well as amyloid-β (Aβ) aggregation [2,9,15,16,17].